Health & Fitness
Health and Fitness
Health and Fitness
Wed, September 15, 2010
Tue, September 14, 2010
Synergy Pharmaceuticals to Present at Roche Colorado Corporation Peptide Symposium 2010
NEW YORK--([ BUSINESS WIRE ])--Synergy Pharmaceuticals, Inc. (OTCBB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that Dr. Kunwar Shailubhai, the Companya™s Chief Scientific Officer, will give an invited talk at the Roche Colorado Corporation Peptide Symposium 2010 to be held on September 14 a" 16 at the St. Julien Hotel and Spa in Boulder, Colorado. Dr. Shailubhaia™s talk entitled aGuanylate Cyclase-C Agonists as a New Class of Drug Candidates for GI Disorders and Inflammatory Bowel Diseasea will be presented on September 15 in Session IA-Peptides in the Clinic.
"Guanylate Cyclase-C Agonists as a New Class of Drug Candidates for GI Disorders and Inflammatory Bowel Disease"
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug plecanatide (formerly called SP-304) is a synthetic analog of the human gastrointestinal hormone uroguanylin, and acts by activating the guanylate cyclase C (GC-C) receptor on epithelial cells of the GI tract. Plecanatide is presently completing a Phase IIa clinical trial of SP-304 in patients to treat chronic constipation. The Company plans to release topline data from this trial in late September 2010, and initiate a Phase IIb 28-day repeated-oral-dose, placebo-controlled trial in chronic constipation patients in late 2010. More information is available at [ http://www.synergypharma.com ].
About Roche Colorado Corporation Peptide Symposisum 2010 (RCCPS)
RCCPS is the key forum for bringing together key decision leaders from both industry and academia to discuss the future of peptide therapeutics. RCCPS seeks to advance the development of effective peptide therapeutics that can be challenged by limited delivery routes, product stability, manufacturing challenges and an evolving regulatory landscape.
